RxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP decreased its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 36.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,000 shares of the company's stock after selling 74,800 shares during the period. Two Sigma Advisers LP owned about 0.33% of RxSight worth $4,538,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RXST. Tidal Investments LLC acquired a new stake in shares of RxSight during the fourth quarter worth about $355,000. State of Wyoming acquired a new stake in RxSight during the 4th quarter worth approximately $37,000. Sherbrooke Park Advisers LLC acquired a new stake in RxSight during the 4th quarter worth approximately $204,000. Silvercrest Asset Management Group LLC purchased a new position in RxSight in the 4th quarter valued at approximately $2,985,000. Finally, Royal Bank of Canada grew its stake in shares of RxSight by 3,094.6% in the fourth quarter. Royal Bank of Canada now owns 508,491 shares of the company's stock worth $17,481,000 after acquiring an additional 492,574 shares in the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $43.00 target price on shares of RxSight in a report on Thursday, April 3rd. Stifel Nicolaus reduced their price target on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Bank of America reissued an "underperform" rating and set a $22.00 price objective (down from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. UBS Group lowered shares of RxSight from a "buy" rating to a "neutral" rating and cut their target price for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Finally, JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $17.00 price target (down previously from $40.00) on shares of RxSight in a research note on Friday, April 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $37.90.

Insider Buying and Selling at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares of the company's stock, valued at approximately $637,428.03. The trade was a 22.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.36% of the stock is currently owned by insiders.

RxSight Trading Down 0.2%

RXST stock traded down $0.04 during trading on Thursday, hitting $16.07. 334,030 shares of the company's stock were exchanged, compared to its average volume of 689,147. The business has a 50-day moving average price of $16.57 and a two-hundred day moving average price of $28.31. The stock has a market capitalization of $652.83 million, a price-to-earnings ratio of -19.37 and a beta of 1.32. RxSight, Inc. has a 52-week low of $12.53 and a 52-week high of $61.10.

RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $38.74 million. During the same quarter in the previous year, the firm earned ($0.25) EPS. The company's revenue was up 28.5% compared to the same quarter last year. On average, equities research analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.